Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer (NCT05563220)
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.
Who can join: Review the eligibility criteria below.
Location: Dothan Hematology and Oncology — Dothan, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (83 Sites)
Showing the first 25 of 83 sites.
- Dothan Hematology and Oncology — Dothan, Alabama
- Mayo Clinic - Arizona — Phoenix, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- City of Hope National Medical Center — Duarte, California
- OPN Healthcare (Los Alamitos Location) — Los Alamitos, California
- Cedars Sinai — Los Angeles, California
- UCLA UCLA Hem/Onc - Clinical Research Unit — Los Angeles, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- TOI Clinical Research — Whittier, California
- Rocky Mountain Cancer Centers — Lone Tree, Colorado
- George Washington Cancer Center — Washington D.C., District of Columbia
- Advent Health (Florida Hospital) - Altamonte Springs — Altamonte Springs, Florida
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital — Chicago, Illinois
- MD Alliance for Multispecialty Research, LLC — Merriam, Kansas
- Johns Hopkins School of Medicine — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- Astera Cancer Care — East Brunswick, New Jersey
- Summit Medical Group — Florham Park, New Jersey
- Cooperman Barnabas Medical Center — New Brunswick, New Jersey
- NYU Langone Health — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.